Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia

Basit Öğe Kaydı
dc.contributor.authorYusof, M. Md
dc.contributor.authorCescon, D. W.
dc.contributor.authorRugo, H. S.
dc.contributor.authorIm, S-A.
dc.contributor.authorGallardo, C.
dc.contributor.authorLipatov, O.
dc.contributor.authorGokmen, E.
dc.date.accessioned2021-05-03T20:36:55Z
dc.date.available2021-05-03T20:36:55Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstract[No Abstract Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncolen_US
dc.description.sponsorshipMerck Sharp Dohme Corp.Merck & Companyen_US
dc.description.sponsorshipMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.en_US
dc.identifier.doi10.1016/j.annonc.2020.10.063
dc.identifier.endpageS1257en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpageS1257en_US
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2020.10.063
dc.identifier.urihttps://hdl.handle.net/11454/70273
dc.identifier.volume31en_US
dc.identifier.wosWOS:000600988900044en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofAnnals of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keyword]en_US
dc.titlePhase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asiaen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu